Track topics on Twitter Track topics that are important to you
Primary Care Providers and specialists involved in diagnosing and treating patients with diabetes are invited to this online, interactive series that will explain and offer guidance on the application of new advancements in IRT starting September 14th.
Boston, MA (PRWEB) September 12, 2017
Joslin Diabetes Center, in partnership with DiabetesSeriesLive, will present a series of live-online CME programs on the evolution of insulin replacement therapy, focusing on new perspectives, evolving technologies, and clinical applications. This educational series is available to clinicians at no cost.
Recent, exciting advances in both the development of pharmacologic tools and technical devices aimed at replicating the normal secretion of insulin in people with diabetes have brought us considerably closer to ideally mimicking natural insulin secretory patterns. However, for these new advances to be optimally utilized, clinicians must be familiar with their indications, usage parameters, and approaches to troubleshooting should the need arise.
“We are excited to present this four-part series of educational programs from the leaders in the space to keep clinicians up to date on the newer insulins and devices,” said Robert Rosenbloom, President and CEO of PlatformQ Health. “It is our hope that the education clinicians access on DiabetesSeriesLive will stimulate learners to think about what they can and should do in their own office setting versus outsource to regional specialty centers, making quality care available to a larger number of patients with diabetes.”
The first one-hour program will air live online Thursday, September 14, 2017 from 3:00-4:00pm ET on DiabetesSeriesLive.com. Richard S. Beaser, MD and Alissa R Segal, PharmD will present Insulin Options for Diabetes: Update on the Evolution. This free online CME session will identify clinically relevant pharmacokinetic and pharmacodynamic properties of the new insulins and insulin combinations, discuss the clinical importance of similarities and differences between a biosimilar insulin and a reference insulin, and describe key, clinically relevant data derived from pivotal trials of new and emerging insulin products. Dr. Beaser is Associate Professor of Medicine at Harvard Medical School and Senior Physician & Medical Director of CME at Joslin Diabetes Center. Dr. Segal is Professor of Pharmacy Practice at Massachusetts College of Pharmacy and Health Sciences (MCPHS) University and Clinical Pharmacist and Diabetes Educator at Joslin Diabetes Center.
Participants will be able to submit questions for the panel prior to and during the live broadcast, to be addressed in real time by the speakers. To submit a question prior to the program, please click here.
“The significant advances in the insulin replacement therapies that are now becoming available empower clinicians caring for people with diabetes to better replicate natural insulin action patterns, but in so doing, challenge those clinicians to learn to take full advantage of these new tools,” shared Dr. Richard Beaser. “Clinicians would therefore benefit from practical, expert-led education in order to understand the full spectrum of insulin replacement therapies which will insure that all of their patients who need these treatment options can have them available in a timely and effective manner. I’m thrilled to help present this series of programs on DiabetesSeriesLive to help arm them to do that.”
The following three additional programs will follow this autumn on http://www.DiabetesSeriesLive.com, expanding on new breakthroughs in insulin therapies:
Advancing to Insulin Therapy for Type 2 Diabetes: The Impact of the New Insulin Options will air live Thursday October, 29, 2017 1:00-2:00pm ET. Topics discussed will include recognizing the indications for advancement to insulin replacement therapy for people with Type 2 Diabetes and applying the important pharmacokinetic and pharmacodynamic properties of the new insulins and insulin combinations to clinical care. Dr Richard Beaser will be joined by Dr. Richard E. Pratley, the Samuel E. Crockett Chair in Diabetes Research; Director at Florida Hospital Diabetes Institute and Adjunct Professor at Sanford Burnham Presbys Medical Discovery Institute.
Physiologic Insulin Replacement: Practical Approaches for the Primary Care Provider will air live Thursday, November 30, 2017 12-1pm. Dr. Richard Beaser will be joined by Dr. Anne L. Peters and Dr. Jeremy H Pettus. Dr. Peters is Director, Clinical Diabetes Program and Professor, Keck School of Medicine at University of Southern California. Dr. Pettus is Assistant Professor of Medicine, Division of Endocrinology at University of California, San Diego.
Dr. Beaser, Dr. Peters and Dr. Pettus will remain for a second program at 1pm ET, titled The Evolution of Glycemic Monitoring and Insulin Delivery Devices: Why the Primary Care Provider Should Understand the Options. This will air live Thursday, November 30, 2017 1-2pm.
The first of these two programs will explore methods to utilize currently available insulins to more accurately replicate natural insulin secretory patterns. In the second program, the use of new devices will be discussed, including insulin pumps and glucose monitoring devices. Practical information will be provided for non-specialist clinicians to help them avail their patients of these tools when indicated.
Each program will be available online on http://www.DiabetesSeriesLive.com for 6 months after its live date for 1.0 AMA PRA Category 1 Credit(s)™, totaling 4.0 CME/ CE credits available for this series. Clinicians can register for the series on DiabetesSeriesLive.
About PlatformQ Health
PlatformQ Health is the leading provider of live, online medical education events, operating 16 therapeutically aligned learning channels dedicated to providing clinicians, patients, caregivers, advocates and administrators rigorous, outcomes-centric education aimed at improving patient care. The company's unique education platform allows participants to connect online from anywhere, to learn about the latest treatments options, and engage in real-time discussion with scientific, research and patient care experts.
About Joslin Diabetes Center
Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S. For more information, visit http://www.joslin.org or follow @joslindiabetes.
For the original version on PRWeb visit: http://www.prweb.com/releases/2017/09/prweb14682337.htmNEXT ARTICLE